By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AmpliMed Corporation 

4380 N. Campbell Avenue
Suite 205
Tucson  Arizona  85718  U.S.A.
Phone: 520-529-1000 Fax: 520-529-3001



Company News
AmpliMed Corporation Reports Results from AMP-019; A Randomized Double Blind Trial of Gemcitabine/Placebo vs. Gemcitabine/Amplimexon in Advanced Pancreatic Cancer 7/12/2010 10:44:11 AM
AmpliMed Corporation Announces License Agreement with Handok Pharmaceuticals for Exclusive Rights to Cancer Therapeutic Amplimexon(R) in Korea 9/10/2008 6:26:38 AM
AmpliMed Corporation to Present Clinical Data from Three Clinical Trials of Amplimexon® at American Society of Clinical Oncology Annual Meeting 5/30/2008 10:19:43 AM
AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer 5/1/2008 10:13:29 AM
AmpliMed Corporation Secures $8.5M In Additional Series B Financing; Oncology Drug Development Company To Use Funds To Achieve Milestones In Clinical Development 11/28/2006 9:58:47 AM
AmpliMed Corporation To Present Positive Phase I Study Results For Amplimexon(R) (imexon for inj.) In Patients With Advanced Solid Tumors 11/10/2006 10:26:00 AM
AmpliMed Corporation Announces Interim Phase I/II Trial Results For Amplimexon Plus Dacarbazine For Treatment Of Malignant Melanoma 9/14/2006 2:09:42 PM
AmpliMed Corporation Announces Interim Phase I/II Trial Results For Amplimexon plus Dacarbazine For Treatment Of Malignant Melanoma; Encouraging Data Presented At Perspectives In Melanoma X And The Third International Melanoma Research Congress In The Netherlands 9/14/2006 9:57:50 AM
AmpliMed Corporation Initiates Phase I Clinical Study Of Benzimate In Patients With Advanced Refractory Cancer 4/28/2006 1:18:10 PM
AmpliMed Corporation Begins Enrollment Of Phase I Trial Of Amplimexon In Patients With Multiple Myeloma 3/28/2006 12:29:26 PM